Tokyo Tape
Sign in
← I'rom Group

Quarterly report · Q2

2372.TEDINET S100S4U1
Period2023-04-01 → 2023-09-30
Filed2023-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥8.7bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥18.4bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥9.6bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥790m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥2.4bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥1.2bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥3.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.5bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥1.4bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥2.6bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥1.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.5bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.1bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥2.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥36.2bnat 2023-09-30Cons.Assets
Total assets¥35.1bnat 2023-03-31Cons.Assets
Total assets¥30.4bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥23.3bnat 2023-09-30Cons.Liabilities
Total liabilities¥23.0bnat 2023-03-31Cons.Liabilities
Net assets / equity¥13.0bnat 2023-09-30Cons.Net assets
Net assets / equity¥12.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥12.0bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥8.9bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥9.4bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥8.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥9.4bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥7.0bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥6.4bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥803m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥3.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥4.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥2.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥17m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥4.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥740m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥90.222023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥16.562023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥210.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥164.172022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥75.82022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥210.062022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥163.912022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio35.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio39.2%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 62
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥250m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥219m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥31m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥542m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥2.4bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥2.4bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥764m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue2023-04-01 → 2023-09-30¥1.7bn
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue external2023-04-01 → 2023-09-30¥844m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥885m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentsegment profit2023-04-01 → 2023-09-30−¥23m
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue2023-04-01 → 2023-09-30¥3.4bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue external2023-04-01 → 2023-09-30¥2.8bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥610m
jpcrp040300-q2r_E05352-000CROreportable segmentsegment profit2023-04-01 → 2023-09-30¥66m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue2023-04-01 → 2023-09-30¥943m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue external2023-04-01 → 2023-09-30¥533m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥409m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentsegment profit2023-04-01 → 2023-09-30−¥35m
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue2023-04-01 → 2023-09-30¥4.8bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue external2023-04-01 → 2023-09-30¥4.3bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥490m
jpcrp040300-q2r_E05352-000SMOreportable segmentsegment profit2023-04-01 → 2023-09-30¥2.1bn
—segment totalrevenue2023-04-01 → 2023-09-30¥10.9bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥8.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥2.4bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥11.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥8.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥2.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥1.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥68m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥28m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥39m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30−¥118m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥641m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥641m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥673m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue2022-04-01 → 2022-09-30¥594m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue external2022-04-01 → 2022-09-30¥592m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentsegment profit2022-04-01 → 2022-09-30−¥184m
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue2022-04-01 → 2022-09-30¥2.8bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue external2022-04-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥88m
jpcrp040300-q2r_E05352-000CROreportable segmentsegment profit2022-04-01 → 2022-09-30¥82m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue2022-04-01 → 2022-09-30¥978m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue external2022-04-01 → 2022-09-30¥528m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥449m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentsegment profit2022-04-01 → 2022-09-30¥28m
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue2022-04-01 → 2022-09-30¥5.8bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.7bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥61m
jpcrp040300-q2r_E05352-000SMOreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.3bn
—segment totalrevenue2022-04-01 → 2022-09-30¥10.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥9.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥601m
—segment totalsegment profit2022-04-01 → 2022-09-30¥3.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥10.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥9.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥641m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥3.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 540
ItemContextValueUnit
Contract liabilitiesPrior1YearInstant372000000JPY
Contract liabilitiesCurrentQuarterInstant575000000JPY
Lease obligations clPrior1YearInstant148000000JPY
Lease obligations clCurrentQuarterInstant167000000JPY
Other clPrior1YearInstant2361000000JPY
Other clCurrentQuarterInstant1925000000JPY
Current liabilitiesPrior1YearInstant12385000000JPY
Current liabilitiesCurrentQuarterInstant12698000000JPY
Long term loans payablePrior1YearInstant8646000000JPY
Long term loans payableCurrentQuarterInstant8547000000JPY
Deferred tax liabilitiesPrior1YearInstant3000000JPY
Deferred tax liabilitiesCurrentQuarterInstant16000000JPY
Asset retirement obligations nclPrior1YearInstant150000000JPY
Asset retirement obligations nclCurrentQuarterInstant162000000JPY
Guarantee deposits received2 nclPrior1YearInstant390000000JPY
Guarantee deposits received2 nclCurrentQuarterInstant390000000JPY
Net defined benefit liabilityPrior1YearInstant170000000JPY
Net defined benefit liabilityCurrentQuarterInstant167000000JPY
Lease obligations nclPrior1YearInstant1183000000JPY
Lease obligations nclCurrentQuarterInstant1187000000JPY
Other nclPrior1YearInstant44000000JPY
Other nclCurrentQuarterInstant116000000JPY
Noncurrent liabilitiesPrior1YearInstant10589000000JPY
Noncurrent liabilitiesCurrentQuarterInstant10587000000JPY
LiabilitiesPrior1YearInstant22974000000JPY
LiabilitiesCurrentQuarterInstant23286000000JPY
Capital stockPrior1YearInstant3899000000JPY
Capital stockCurrentQuarterInstant3899000000JPY
Capital surplusPrior1YearInstant1495000000JPY
Capital surplusCurrentQuarterInstant1495000000JPY
Retained earningsPrior1YearInstant7036000000JPY
Retained earningsCurrentQuarterInstant7765000000JPY
Treasury stockPrior1YearInstant-424000000JPY
Treasury stockCurrentQuarterInstant-424000000JPY
Shareholders equityPrior1YearInstant12006000000JPY
Shareholders equityCurrentQuarterInstant12736000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant107000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant186000000JPY
Foreign currency translation adjustmentPrior1YearInstant33000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant32000000JPY
Valuation and translation adjustmentsPrior1YearInstant141000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant219000000JPY
Non controlling interestsPrior1YearInstant6000000JPY
Non controlling interestsCurrentQuarterInstant6000000JPY
Net assetsPrior1YearInstant12154000000JPY
Net assetsCurrentQuarterInstant12962000000JPY
Liabilities and net assetsPrior1YearInstant35129000000JPY
Liabilities and net assetsCurrentQuarterInstant36248000000JPY
Net salesPrior1YTDDuration9639000000JPY
Net salesCurrentYTDDuration8678000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass